menu
    • menu
    [{"orgOrder":0,"company":"Certara","sponsor":"Defence Materials Technology Centre","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Certara \/ Certara","highestDevelopmentStatusID":"11","companyTruncated":"Certara \/ Certara"},{"orgOrder":0,"company":"Certara","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Certara \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Certara \/ Galderma"},{"orgOrder":0,"company":"Certara","sponsor":"Ichnos Glenmark Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"ISB 2001","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Certara \/ Certara","highestDevelopmentStatusID":"6","companyTruncated":"Certara \/ Certara"},{"orgOrder":0,"company":"Certara","sponsor":"Arvinas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Certara \/ Arvinas","highestDevelopmentStatusID":"1","companyTruncated":"Certara \/ Arvinas"}]

    Find Clinical Drug Pipeline Developments & Deals by Certara

    Menu

    Certara

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Certara

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Certara

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Ichnos Glenmark Innovation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Certara and Ichnos Glenmark Collaborate On Cancer Drug Dosing Optimization

                            Details : ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 18, 2024

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Ichnos Glenmark Innovation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Certara

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Certara

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Arvinas

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Arvinas picks Certara for Its Targeted Protein Degradation Research

                            Details : Certara’s D360 platform enables Arvinas to accelerate lead identification and optimization processes for oncology, neurodegenerative diseases, and therapies for “undruggable” targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 02, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Arvinas

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Certara

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Certara

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trifarotene

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Galderma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Certara Partners with Galderma in Advancing Modeling and Simulation Technology to Attain FDA Approval of AKLIE...

                            Details : Certara's Simcyp population-based Simulator was used to support Galderma’s successful U.S. FDA new drug application for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.

                            Product Name : Aklief

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 01, 2020

                            Lead Product(s) : Trifarotene

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Galderma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Certara

                            U.S.A arrow
                            IFSCC
                            Not Confirmed

                            Certara

                            U.S.A arrow
                            IFSCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Recipient : Defence Materials Technology Centre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Worke...

                            Details : Certara will support the DMTC led clinical trial by analyzing study data to develop mathematical models to understand viral time course and factors impacting drug exposure and prophylactic response.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 05, 2020

                            Lead Product(s) : Chloroquine Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Recipient : Defence Materials Technology Centre

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth